{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:57:20Z","timestamp":1791518240315,"version":"4.3.4"},"reference-count":36,"publisher":"American Society for Microbiology","issue":"10","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/501100000781","name":"EC | European Research Council","doi-asserted-by":"publisher","award":["614739-A_HERO"],"award-info":[{"award-number":["614739-A_HERO"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2016,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The current treatments against\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Trichuris trichiura<\/jats:named-content>\n            , albendazole and mebendazole, are only poorly efficacious. Therefore, combination chemotherapy was recommended for treating soil-transmitted helminthiasis. Albendazole-mebendazole and albendazole-oxantel pamoate have shown promising results in clinical trials. However,\n            <jats:italic>in vitro<\/jats:italic>\n            and\n            <jats:italic>in vivo<\/jats:italic>\n            drug interaction studies should be performed before their simultaneous treatment can be recommended. Inhibition of human recombinant cytochromes P450 (CYPs) CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 was tested by exposure to albendazole, albendazole sulfoxide, mebendazole, and oxantel pamoate, as well as albendazole-mebendazole, albendazole sulfoxide-mebendazole, albendazole-oxantel pamoate, and albendazole sulfoxide-oxantel pamoate. A high-pressure liquid chromatography (HPLC)-UV\/visible spectroscopy method was developed and validated for simultaneous quantification of albendazole sulfoxide, albendazole sulfone, mebendazole, and oxantel pamoate in plasma. Albendazole, mebendazole, oxantel pamoate, albendazole-mebendazole, and albendazole-oxantel pamoate were orally applied to rats (100 mg\/kg) and pharmacokinetic parameters calculated. CYP1A2 showed a 2.6-fold increased inhibition by albendazole-oxantel pamoate (50% inhibitory concentration [IC\n            <jats:sub>50<\/jats:sub>\n            ] = 3.1 \u03bcM) and a 3.9-fold increased inhibition by albendazole sulfoxide-mebendazole (IC\n            <jats:sub>50<\/jats:sub>\n            = 3.8 \u03bcM) compared to the single drugs. In rats, mebendazole's area under the concentration-time curve (AUC) and maximal plasma concentration (\n            <jats:italic>C<\/jats:italic>\n            <jats:sub>max<\/jats:sub>\n            ) were augmented 3.5- and 2.8-fold, respectively (\n            <jats:italic>P<\/jats:italic>\n            = 0.02 for both) when coadministered with albendazole compared to mebendazole alone. Albendazole sulfone was slightly affected by albendazole-mebendazole, displaying a 1.3-fold-elevated AUC compared to albendazole alone. Oxantel pamoate could not be quantified, translating to a bioavailability below 0.025% in rats. Elevated plasma levels of albendazole sulfoxide, albendazole sulfone, and mebendazole in coadministrations are probably not mediated by CYP-based drug-drug interaction. Even though this study indicates that it is safe to coadminister albendazole-oxantel pamoate and albendazole-mebendazole, human pharmacokinetic studies are recommended.\n          <\/jats:p>","DOI":"10.1128\/aac.01217-16","type":"journal-article","created":{"date-parts":[[2016,8,2]],"date-time":"2016-08-02T03:04:34Z","timestamp":1470107074000},"page":"6127-6133","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":13,"title":["<i>In Vitro<\/i>\n            and\n            <i>In Vivo<\/i>\n            Drug Interaction Study of Two Lead Combinations, Oxantel Pamoate plus Albendazole and Albendazole plus Mebendazole, for the Treatment of Soil-Transmitted Helminthiasis"],"prefix":"10.1128","volume":"60","author":[{"given":"Noemi","family":"Cowan","sequence":"first","affiliation":[{"name":"Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Basel, Switzerland"},{"name":"University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireille","family":"Vargas","sequence":"additional","affiliation":[{"name":"Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Basel, Switzerland"},{"name":"University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Keiser","sequence":"additional","affiliation":[{"name":"Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Basel, Switzerland"},{"name":"University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1186\/1756-3305-7-37"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/657310"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.trstmh.2011.07.009"},{"key":"e_1_3_2_5_2","volume-title":"A roadmap for implementation","author":"World Health Organization","year":"2012","unstructured":"World Health Organization. 2012. Accelerating work to overcome the global impact of neglected tropical diseases. A roadmap for implementation. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.1999.60.479"},{"key":"e_1_3_2_7_2","first-page":"35","article-title":"A comparison of the efficacy of single doses of albendazole, ivermectin, and diethylcarbamazine alone or in combinations against Ascaris and Trichuris spp","volume":"81","author":"Belizario VY","year":"2003","unstructured":"Belizario VY, Amarillo ME, de Leon WU, de los Reyes AE, Bugayong MG, Macatangay BJC. 2003. A comparison of the efficacy of single doses of albendazole, ivermectin, and diethylcarbamazine alone or in combinations against Ascaris and Trichuris spp. Bull World Health Organ 81:35\u201342.","journal-title":"Bull World Health Organ"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)71050-3"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1179\/000349803235001697"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2007.76.1153"},{"key":"e_1_3_2_11_2","volume-title":"Introduction to drug metabolism","author":"Gibson GG","year":"2001","unstructured":"Gibson GG, Skett P. 2001. Introduction to drug metabolism, 3rd ed. Cengage Learning, Boston, MA.","edition":"3"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1851"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.0306-5251.2001.temp.1441.x"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.31.8.1005"},{"key":"e_1_3_2_15_2","volume-title":"Early drug development: strategies and routes to first-in-Human trials","author":"Cayen MN","year":"2011","unstructured":"Cayen MN. 2011. Early drug development: strategies and routes to first-in-Human trials. John Wiley & Sons, New York, NY."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2000.00170.x"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0001-706X(03)00031-7"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-015-0243-9"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.113.051177"},{"key":"e_1_3_2_20_2","volume-title":"Pfizer technical report","author":"Pfizer","year":"1973","unstructured":"Pfizer. 1973. A study of absorption of CP-14,445, a new pamoate, in man. Pfizer technical report. Pfizer, New York, NY."},{"key":"e_1_3_2_21_2","volume-title":"Vivid\u00ae CYP450 screening kits user guide","author":"Life Technologies","year":"2012","unstructured":"Life Technologies. 2012. Vivid\u00ae CYP450 screening kits user guide. Life Technologies, Carlsbad, CA."},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1177\/1087057104269731"},{"key":"e_1_3_2_23_2","volume-title":"Guidance for industry\u2014bioanalytical method validation, May","author":"Food and Drug Administration","year":"2001","unstructured":"Food and Drug Administration. 2001. Guidance for industry\u2014bioanalytical method validation, May. Food and Drug Administration, Washington, DC."},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1124\/pr.58.3.10"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2010.01.007"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-60761-849-2_1"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0001138"},{"key":"e_1_3_2_28_2","first-page":"30","article-title":"Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s","volume":"29","author":"Bapiro TE","year":"2001","unstructured":"Bapiro TE, Egnell AC, Hasler JA, Masimirembwa CM. 2001. Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos 29:30\u201335.","journal-title":"Drug Metab Dispos"},{"key":"e_1_3_2_29_2","first-page":"97","article-title":"Inhibitory effect of albendazole and its metabolites on cytochromes P450 activities in rat and mouflon in vitro","volume":"57","author":"Baliharov\u00e1 V","year":"2005","unstructured":"Baliharov\u00e1 V, Vel\u00edk J, Fimanov\u00e1 K, Lamka J, Szot\u00e1kov\u00e1 B, Savl\u00edk M, Sk\u00e1lov\u00e1 L. 2005. Inhibitory effect of albendazole and its metabolites on cytochromes P450 activities in rat and mouflon in vitro. Pharmacol Rep 57:97\u2013106.","journal-title":"Pharmacol Rep"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/0169-4758(90)90228-V"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1986.tb05179.x"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-5173(03)00369-7"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.104.003319"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpddr.2011.10.001"},{"key":"e_1_3_2_35_2","first-page":"72","article-title":"Blood volume in the rat","volume":"26","author":"Lee HB","year":"1985","unstructured":"Lee HB, Blaufox MD. 1985. Blood volume in the rat. J Nucl Med 26:72\u201376.","journal-title":"J Nucl Med"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1080\/00498250600571749"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.299.16.1937"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01217-16","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01217-16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T23:09:59Z","timestamp":1645484999000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01217-16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["10.1128\/AAC.01217-16"],"URL":"https:\/\/doi.org\/10.1128\/aac.01217-16","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"2016-06-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-07-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-09-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}